Human Genome Sciences Inc., a GSK Company
14
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
50%
7 trials in Phase 3/4
83%
10 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
Role: collaborator
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Role: lead
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Role: lead
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
Role: lead
A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
Role: lead
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Role: lead
A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
Role: lead
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
Role: lead
Belimumab in Remission of VASculitis
Role: lead
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
Role: lead
A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
Role: lead
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
Role: lead
Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99
Role: lead
A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Role: lead
All 14 trials loaded